Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: AgFinder who wrote (2525)	4/23/1999 2:56:00 AM
From: AgFinder	Respond to of 10280

Top 10 DTC Products Advertised January-October, 1998: Claritin (Schering-Plough): $127.4 (millions) Zyrtec (Pfizer): 70.8 Propecia (Merck): 70.2 Pravachol (BMS): 59 Allegra (HMR): 51.8 Zyban (Glaxo): 40.8 Prilosec (Astra): 40.8 Evista (Lilly): 38.7 Prozac (Lilly): 37.5 Flonase (Glaxo): 35.6 SOURCE: Scott-Levin, Direct to Consumer Advertising Audit ----------------- So, SEPR has a 1/3 $Billion ad budget without paying a dime ? Ag.

To: AgFinder who wrote (2525)	4/23/1999 3:23:00 AM
From: AgFinder	Respond to of 10280

More from Scott-Levin: "In 1998, visits to office-based primary care doctors for high blood pressure rose 2% over 1997, to 62.3 million. The most-prescribed hypertension medicine was Pfizer's Norvasc, with 7.7 million prescriptions written." ------------------ According to Pfizers 1998 annual report, 1998 sales of Norvasc were 2.6 Billion. Looks like Dave needs to adjust the model accordingly. Ag. -------------- "Feb. 24, 1999--Patient visits to physicians for depressive disorders rose 10%, to 19 million, during the 12 months ending November 1998, according to the pharmaceutical consulting firm Scott-Levin. Those who sought treatment for depression received pharmaceutical therapy during 93% of those visits, notes Scott-Levin's Physician Drug & Diagnosis Audit, a monthly service that tracks patient visits to doctors and the reasons for them." Ag.